Developer docs
API playgroundTry for free, no card

Search company profiles

Kriya Therapeutics

Full company profile

uuid00002ck

Namestring
Kriya Therapeutics
Legal namestring
Kriya Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Kriya Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 that develops adeno-associated virus (AAV)-based gene therapies for patients with chronic, prevalent diseases across three therapeutic areas: ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company's lead assets include KRIYA-825 (Phase 1/2 for Geographic Atrophy), KRIYA-586 (Thyroid Eye Disease), KRIYA-839 (Type 1 Diabetes), KRIYA-497 (MASH via FGF21 expression), and KRIYA-748 (Trigeminal Neuralgia using a chemogenetically-gated ion channel). Kriya differentiates from earlier-generation gene therapy companies by targeting diseases affecting millions of patients rather than rare monogenic disorders, applying validated biological pathways with one-time AAV administration to deliver durable therapeutic protein expression.

Kriya operates a fully integrated platform consisting of two proprietary technology engines: SIRVE (System for Intelligent Rational Vector Engineering), a computationally-enabled platform for rational AAV vector design that uses generative deep learning, AlphaFold-based protein screening, and machine-learning-guided splicing elements to optimize expression, tissue specificity, manufacturability, and stability; and STRIPE (System to Realize Improved Production Efficiency), a scalable GMP manufacturing platform integrated with cell line technology and upstream/downstream process advances, located in a 51,350 sq ft facility in Research Triangle Park, NC with 50L, 500L, and 3,000L bioreactor capacity. The company augments these platforms with strategic in-licensing (e.g., the CR2-CR1 complement inhibitor from MUSC, Everads' suprachoroidal delivery technology) and acquisitions (Redpin Therapeutics for neurology in 2022; Tramontane Therapeutics for FGF21 metabolic assets in 2023). Key personnel include former leadership from Spark Therapeutics, AveXis, Sangamo, Pfizer, bluebird bio, and United Therapeutics, several of whom contributed to FDA-approved gene therapies (Luxturna, Kymriah, Beqvez, Zolgensma).

Kriya is pre-revenue. All pipeline programs are investigational and have not yet been approved; the company plans to commercialize gene therapy products upon regulatory approval, with distribution expected to flow through specialty pharmacies and hospital channels typical for biologics. The business model is therefore dependent on continued equity financing until first approval — the company has raised over $1.2 billion in venture capital across six rounds from Patient Square Capital (lead investor across Series B, C, and D), Premji Invest, Foresite Capital, QVT, Narya Capital, Dexcel Pharma, Bluebird Ventures, Woodline Partners, the T1D Fund, Peter Thiel, and others. Customer engagement currently runs through investigator-site clinical trials (Phase 1/2 underway for KRIYA-825, with additional programs planned to enter the clinic in 2025), medical conference presence (ASGCT, ARVO, ESOPRS), and peer-reviewed publications, with no commercial sales force, pricing, or distribution channel disclosed.

Short descriptiontext

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for ophthalmology, metabolic disease, and neurology, targeting prevalent chronic conditions like Geographic Atrophy, Type 1 Diabetes, MASH, and Trigeminal Neuralgia using its proprietary SIRVE computational vector design and STRIPE scalable GMP manufacturing platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, biopharmaceutical products, AAV vector engineering, clinical-stage therapeutics, genetic medicines
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Product Sales
TypeOne Time License
Description

Kriya is a clinical-stage biopharmaceutical company developing a pipeline of gene therapies. Upon regulatory approval, the company plans to commercialize its gene therapy products. All programs are investigational and not yet approved. No revenue has been generated to date.

kriyatherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing adeno-associated virus (AAV)-based gene therapies for prevalent chronic diseases in ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company operates a fully integrated platform that combines proprietary computational vector design (SIRVE) with scalable in-house GMP manufacturing (STRIPE) and AI-enabled analytics. All programs are investigational and not yet approved.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • KRIYA-825 demonstrated dose-dependent preservation of retinal thickness and suppression of C3b to iC3b protein levels in mouse model of sodium iodate-induced retinal degeneration
+3 more records
Product overview1 text field

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of gene therapies across three therapeutic areas: ophthalmology (KRIYA-825 for Geographic Atrophy, KRIYA-586 for Thyroid Eye Disease), metabolic disease (KRIYA-839 for Diabetes, KRIYA-497 for MASH), and neurology (KRIYA-748 for Trigeminal Neuralgia, KRIYA-382 for Focal Epilepsy). The company operates on two proprietary technology platforms: SIRVE for computational vector engineering and STRIPE for scalable GMP manufacturing. Early pipeline programs include KT-A112, KT-A522, and KT-A832. The company has in-house manufacturing capabilities in Research Triangle Park, North Carolina with GMP production capacity at 50L, 500L, and 3,000L scale.

Product and service4 records
1KRIYA-825
CategoryGene Therapy Product
Description

AAV-based gene therapy expressing a complement CR2-CR1 fusion protein inhibitor for the treatment of Geographic Atrophy, designed for one-time suprachoroidal injection to inhibit complement C3 and C5 in the retina. Licensed from MUSC. For patients with Geographic Atrophy (approximately 2 million in US/EU).

2KRIYA-586
CategoryGene Therapy Product
Description

AAV gene therapy expressing an anti-IGF1R antibody for Thyroid Eye Disease, designed for one-time peribulbar injection with localized antibody expression in extraocular muscles and fat tissue. For patients with Thyroid Eye Disease (approximately 1 million in US/EU).

3KRIYA-839
CategoryGene Therapy Product
Description

AAV-based gene therapy providing insulin and glucokinase for diabetes treatment, delivered intramuscularly with the objective of driving durable glycemic control. For patients with Type 1 Diabetes (approximately 17 million insulin-using diabetics in US/EU).

4KRIYA-497
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-27
Description

Kriya entered into an exclusive license, collaboration and supply agreement with Everads Therapy for the use of Everads' suprachoroidal delivery technology for Kriya's gene therapies for retinal diseases including Geographic Atrophy. Everads developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space. Kriya is using this for KRIYA-825 and other ophthalmology programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-06
Description

Kriya acquired Tramontane Therapeutics, a private gene therapy company focused on metabolic and neurodegenerative diseases including NASH. Tramontane is a spin out from Universitat Autònoma de Barcelona (UAB) and is now a wholly owned subsidiary of Kriya. The acquisition added portfolio of FGF21 assets including a lead AAV program expressing native FGF21 protein.

3Redpin Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-16
Description

Kriya acquired Redpin Therapeutics, adding a neurology pipeline to its gene therapy portfolio. Redpin focused on developing gene therapies for neurological conditions.

kriyatherapeutics.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-26
Description

Kriya entered into an exclusive license agreement with the MUSC Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of Geographic Atrophy and other ocular diseases. This formed the basis for KRIYA-825 (AAV2.CR2-CR1).

5Universitat Autònoma de Barcelona (UAB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-12
Description

Kriya established partnerships with leading academic and research institutions including UAB for FGF21 gene therapy research. UAB researchers (led by Prof. Fátima Bosch) generated preclinical data for KRIYA-497 published in Molecular Therapy, demonstrating fibrosis reversal in MASH models. Prof. Bosch serves on Kriya's Scientific Advisory Board.

kriyatherapeutics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-12
Description

Kriya established partnerships with leading academic and research institutions, including the U.S. National Institutes of Health (NIH), as part of its platform infrastructure development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AAV gene therapy platform company with proprietary NAV vector technology and pipeline across ophthalmology, metabolic, and CNS indications. Highly comparable to Kriya as another platform-based AAV developer pursuing prevalent and rare disease gene therapies.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for ophthalmology, including wet AMD and diabetic macular edema. Direct competitor in ocular gene therapy space, especially relevant to Kriya's KRIYA-825 program in retinal disease.

TypeDirect peer
Description

Clinical-stage gene therapy company with programs in cardiology and CNS, leveraging AAV and other delivery platforms. Comparable platform-based gene therapy developer with similar stage and capital base to Kriya.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on cardiac disease using AAV and other modalities. Comparable clinical-stage AAV developer with similar funding scale, headcount, and pipeline depth.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable platform-based AAV developer at similar clinical and capital stage.

TypeDirect peer
Description

Clinical-stage gene therapy company with integrated manufacturing capabilities and pipeline spanning ophthalmology, CNS, and salivary gland gene therapies. Direct platform peer to Kriya with shared focus on prevalent disease gene therapy and internal GMP manufacturing.

TypeDirect peer
Description

Clinical and commercial-stage gene therapy company with one approved AAV gene therapy (Hemgenix for hemophilia B). Closest direct peer given AAV platform, multiple clinical programs, and integrated manufacturing capabilities.

8bluebird bio
TypeDirect peer
Description

Gene therapy company with multiple approved products (Zynteglo, Lyfgenia, Skysona). Comparable gene therapy developer with approved AAV-based and lentiviral products, similar pioneering gene therapy profile to Kriya.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing non-viral gene therapy using closed-ended DNA (ceDNA) platform. Emerging platform peer targeting similar chronic and rare diseases with a differentiated non-AAV delivery approach.

TypeBroad incumbent
Description

Established genomic medicine company with multiple gene therapy and gene editing programs across rare disease. Broad incumbent in the gene therapy space; comparable to Kriya through partnership/alliance relationships (Roger Jeffs previously on Sangamo board; Sangamo alumni Zhu Pirot at Kriya).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kriya Therapeutics

Gene Therapy Pharmaceuticalskriyatherapeutics.com

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for ophthalmology, metabolic disease, and neurology, targeting prevalent chronic conditions like Geographic Atrophy, Type 1 Diabetes, MASH, and Trigeminal Neuralgia using its proprietary SIRVE computational vector design and STRIPE scalable GMP manufacturing platforms.

What Kriya Therapeutics does

Kriya Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 that develops adeno-associated virus (AAV)-based gene therapies for patients with chronic, prevalent diseases across three therapeutic areas: ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company's lead assets include KRIYA-825 (Phase 1/2 for Geographic Atrophy), KRIYA-586 (Thyroid Eye Disease), KRIYA-839 (Type 1 Diabetes), KRIYA-497 (MASH via FGF21 expression), and KRIYA-748 (Trigeminal Neuralgia using a chemogenetically-gated ion channel). Kriya differentiates from earlier-generation gene therapy companies by targeting diseases affecting millions of patients rather than rare monogenic disorders, applying validated biological pathways with one-time AAV administration to deliver durable therapeutic protein expression.

Kriya operates a fully integrated platform consisting of two proprietary technology engines: SIRVE (System for Intelligent Rational Vector Engineering), a computationally-enabled platform for rational AAV vector design that uses generative deep learning, AlphaFold-based protein screening, and machine-learning-guided splicing elements to optimize expression, tissue specificity, manufacturability, and stability; and STRIPE (System to Realize Improved Production Efficiency), a scalable GMP manufacturing platform integrated with cell line technology and upstream/downstream process advances, located in a 51,350 sq ft facility in Research Triangle Park, NC with 50L, 500L, and 3,000L bioreactor capacity. The company augments these platforms with strategic in-licensing (e.g., the CR2-CR1 complement inhibitor from MUSC, Everads' suprachoroidal delivery technology) and acquisitions (Redpin Therapeutics for neurology in 2022; Tramontane Therapeutics for FGF21 metabolic assets in 2023). Key personnel include former leadership from Spark Therapeutics, AveXis, Sangamo, Pfizer, bluebird bio, and United Therapeutics, several of whom contributed to FDA-approved gene therapies (Luxturna, Kymriah, Beqvez, Zolgensma).

Kriya is pre-revenue. All pipeline programs are investigational and have not yet been approved; the company plans to commercialize gene therapy products upon regulatory approval, with distribution expected to flow through specialty pharmacies and hospital channels typical for biologics. The business model is therefore dependent on continued equity financing until first approval — the company has raised over $1.2 billion in venture capital across six rounds from Patient Square Capital (lead investor across Series B, C, and D), Premji Invest, Foresite Capital, QVT, Narya Capital, Dexcel Pharma, Bluebird Ventures, Woodline Partners, the T1D Fund, Peter Thiel, and others. Customer engagement currently runs through investigator-site clinical trials (Phase 1/2 underway for KRIYA-825, with additional programs planned to enter the clinic in 2025), medical conference presence (ASGCT, ARVO, ESOPRS), and peer-reviewed publications, with no commercial sales force, pricing, or distribution channel disclosed.

Kriya Therapeutics firmographics

Firmographics
Name
Kriya Therapeutics
Legal name
Kriya Therapeutics, Inc.
Website
https://kriyatherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for ophthalmology, metabolic disease, and neurology, targeting prevalent chronic conditions like Geographic Atrophy, Type 1 Diabetes, MASH, and Trigeminal Neuralgia using its proprietary SIRVE computational vector design and STRIPE scalable GMP manufacturing platforms.
Ownership category
akta.pro rank

Kriya Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Biopharmaceutical products
  • AAV vector engineering
  • Clinical-stage therapeutics
  • Genetic medicines

Where Kriya Therapeutics is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kriya Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

  1. Gene Therapy Product Sales: Kriya is a clinical-stage biopharmaceutical company developing a pipeline of gene therapies. Upon regulatory approval, the company plans to commercialize its gene therapy products. All programs are investigational and not yet approved. No revenue has been generated to date.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Kriya Therapeutics product offering

Product offering

Core offering

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing adeno-associated virus (AAV)-based gene therapies for prevalent chronic diseases in ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company operates a fully integrated platform that combines proprietary computational vector design (SIRVE) with scalable in-house GMP manufacturing (STRIPE) and AI-enabled analytics. All programs are investigational and not yet approved.

Product overview

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of gene therapies across three therapeutic areas: ophthalmology (KRIYA-825 for Geographic Atrophy, KRIYA-586 for Thyroid Eye Disease), metabolic disease (KRIYA-839 for Diabetes, KRIYA-497 for MASH), and neurology (KRIYA-748 for Trigeminal Neuralgia, KRIYA-382 for Focal Epilepsy). The company operates on two proprietary technology platforms: SIRVE for computational vector engineering and STRIPE for scalable GMP manufacturing. Early pipeline programs include KT-A112, KT-A522, and KT-A832. The company has in-house manufacturing capabilities in Research Triangle Park, North Carolina with GMP production capacity at 50L, 500L, and 3,000L scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • KRIYA-825 AAV-based gene therapy expressing a complement CR2-CR1 fusion protein inhibitor for the treatment of Geographic Atrophy, designed for one-time suprachoroidal injection to inhibit complement C3 and C5 in the retina. Licensed from MUSC. For patients with Geographic Atrophy (approximately 2 million in US/EU).
  • KRIYA-586 AAV gene therapy expressing an anti-IGF1R antibody for Thyroid Eye Disease, designed for one-time peribulbar injection with localized antibody expression in extraocular muscles and fat tissue. For patients with Thyroid Eye Disease (approximately 1 million in US/EU).
  • KRIYA-839 AAV-based gene therapy providing insulin and glucokinase for diabetes treatment, delivered intramuscularly with the objective of driving durable glycemic control. For patients with Type 1 Diabetes (approximately 17 million insulin-using diabetics in US/EU).
  • KRIYA-497

Quantifiable outcome

  • KRIYA-825 demonstrated dose-dependent preservation of retinal thickness and suppression of C3b to iC3b protein levels in mouse model of sodium iodate-induced retinal degeneration
  • +3 more outcomes

Companies that use Kriya Therapeutics

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Kriya Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Kriya Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Everads TherapycoreTechnology or Integration · 27 September 2023Kriya entered into an exclusive license, collaboration and supply agreement with Everads Therapy for the use of Everads' suprachoroidal delivery technology for Kriya's gene therapies for retinal diseases including Geographic Atrophy. Everads developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space. Kriya is using this for KRIYA-825 and other ophthalmology programs.
  • Tramontane TherapeuticscoreStrategic or Co-development Partner · 6 September 2023Kriya acquired Tramontane Therapeutics, a private gene therapy company focused on metabolic and neurodegenerative diseases including NASH. Tramontane is a spin out from Universitat Autònoma de Barcelona (UAB) and is now a wholly owned subsidiary of Kriya. The acquisition added portfolio of FGF21 assets including a lead AAV program expressing native FGF21 protein.
  • Redpin TherapeuticscoreStrategic or Co-development Partner · 16 November 2022Kriya acquired Redpin Therapeutics, adding a neurology pipeline to its gene therapy portfolio. Redpin focused on developing gene therapies for neurological conditions.
  • Medical University of South Carolina (MUSC) Foundation for Research DevelopmentcoreTechnology or Integration · 26 January 2022Kriya entered into an exclusive license agreement with the MUSC Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of Geographic Atrophy and other ocular diseases. This formed the basis for KRIYA-825 (AAV2.CR2-CR1).
  • Universitat Autònoma de Barcelona (UAB)coreStrategic or Co-development Partner · 12 May 2020Kriya established partnerships with leading academic and research institutions including UAB for FGF21 gene therapy research. UAB researchers (led by Prof. Fátima Bosch) generated preclinical data for KRIYA-497 published in Molecular Therapy, demonstrating fibrosis reversal in MASH models. Prof. Bosch serves on Kriya's Scientific Advisory Board.
  • NIH (U.S. National Institutes of Health)minorStrategic or Co-development Partner · 12 May 2020Kriya established partnerships with leading academic and research institutions, including the U.S. National Institutes of Health (NIH), as part of its platform infrastructure development.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Kriya Therapeutics competitors and assessment

Company assessment

Direct peers

  • Regenxbio: Clinical-stage AAV gene therapy platform company with proprietary NAV vector technology and pipeline across ophthalmology, metabolic, and CNS indications. Highly comparable to Kriya as another platform-based AAV developer pursuing prevalent and rare disease gene therapies.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ophthalmology, including wet AMD and diabetic macular edema. Direct competitor in ocular gene therapy space, especially relevant to Kriya's KRIYA-825 program in retinal disease.
  • Lexeo Therapeutics: Clinical-stage gene therapy company with programs in cardiology and CNS, leveraging AAV and other delivery platforms. Comparable platform-based gene therapy developer with similar stage and capital base to Kriya.
  • Tenaya Therapeutics: Clinical-stage gene therapy company focused on cardiac disease using AAV and other modalities. Comparable clinical-stage AAV developer with similar funding scale, headcount, and pipeline depth.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable platform-based AAV developer at similar clinical and capital stage.
  • MeiraGTx: Clinical-stage gene therapy company with integrated manufacturing capabilities and pipeline spanning ophthalmology, CNS, and salivary gland gene therapies. Direct platform peer to Kriya with shared focus on prevalent disease gene therapy and internal GMP manufacturing.
  • uniQure: Clinical and commercial-stage gene therapy company with one approved AAV gene therapy (Hemgenix for hemophilia B). Closest direct peer given AAV platform, multiple clinical programs, and integrated manufacturing capabilities.
  • bluebird bio: Gene therapy company with multiple approved products (Zynteglo, Lyfgenia, Skysona). Comparable gene therapy developer with approved AAV-based and lentiviral products, similar pioneering gene therapy profile to Kriya.

Emerging players

  • Generation Bio: Clinical-stage genetic medicines company developing non-viral gene therapy using closed-ended DNA (ceDNA) platform. Emerging platform peer targeting similar chronic and rare diseases with a differentiated non-AAV delivery approach.

Broad incumbents

  • Sangamo Therapeutics: Established genomic medicine company with multiple gene therapy and gene editing programs across rare disease. Broad incumbent in the gene therapy space; comparable to Kriya through partnership/alliance relationships (Roger Jeffs previously on Sangamo board; Sangamo alumni Zhu Pirot at Kriya).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kriya Therapeutics social profiles

Digital presence

Kriya Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kriya Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Kriya Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Kriya Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kriya Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kriya Therapeutics

What does Kriya Therapeutics do?

Kriya Therapeutics is a clinical-stage biopharmaceutical company developing adeno-associated virus (AAV)-based gene therapies for prevalent chronic diseases in ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company operates a fully integrated platform that combines proprietary computational vector design (SIRVE) with scalable in-house GMP manufacturing (STRIPE) and AI-enabled analytics. All programs are investigational and not yet approved.

Is Kriya Therapeutics a public or private company?

Kriya Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kriya Therapeutics founded?

Kriya Therapeutics was founded in 2019. It employs 101 to 250 people.

Where is Kriya Therapeutics based?

Kriya Therapeutics is headquartered in Morrisville, United States, in the North America region.

How does Kriya Therapeutics make money?

One revenue line is on record: gene Therapy Product Sales.

Who are Kriya Therapeutics's main competitors?

Direct peers on record are Regenxbio, Adverum Biotechnologies, Lexeo Therapeutics, Tenaya Therapeutics, Solid Biosciences, MeiraGTx, uniQure and bluebird bio. Generation Bio is listed as an emerging player. Sangamo Therapeutics is listed as a broad incumbent.

Does Kriya Therapeutics have an API?

No public API is recorded for Kriya Therapeutics.

What industry is Kriya Therapeutics in?

Kriya Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageKriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged MiceKriya Therapeutics announced preclinical data showing that a single intramuscular administration of AAV-FGF21 gene therapy extended median lifespan by more than 20% in naturally aged mice, with preserved organ function across liver, kidney, heart, and muscle systems. The study, led by researchers at the Universitat Autònoma de Barcelona and published in Molecular Therapy, demonstrated that treated animals maintained body weight, improved insulin sensitivity, and showed enhanced mitochondrial function and reduced inflammation. Kriya is advancing KRIYA-497, its one-time gene therapy candidate expressing human native FGF21, in a clinical trial for patients with metabolic dysfunction-associated steatohepatitis (MASH).MorningstarKriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged MiceKriya Therapeutics published preclinical data showing a single intramuscular AAV-FGF21 dose extended health span and lifespan by over 20% in aged mice. The therapy preserved organ function and improved metabolic parameters, reinforcing its potential for steatotic liver disease. KRIYA-497 is in a clinical trial for MASH.Fox NewsNew FDA moves are boosting American jobs and protecting our medicine supplyFDA Commissioner Marty Makary outlined the agency's implementation of Executive Order 14293 to promote domestic pharmaceutical manufacturing, including the launch of the PreCheck Pilot Program to streamline facility approvals that previously caused up to 14-month delays. The FDA selected seven pharmaceutical companies—Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin—to participate in the program's early phases, with these companies expected to create thousands of high-wage manufacturing jobs. The Department of Health and Human Services also launched "Operation TrialBlazer" to bring clinical trials back to American soil as part of broader efforts to reshore pharmaceutical production.PharmaCommerceFAQ: Where US Pharma Reshoring Stands in 2026A new Section 232 tariff regime imposing up to 100% duties on patented pharmaceuticals, APIs, and key starting materials takes effect July 31, 2026 for Annex III firms and September 29, 2026 for others, with pathways to reduced rates for companies with approved onshoring plans or Most Favored Nation pricing agreements. The FDA's PreCheck Pilot Program, launched in February 2026, is supporting eight manufacturers—including Amneal, Cellares, Eli Lilly, FUJIFILM Biotechnologies, Kriya Therapeutics, Kyowa Kirin, and Regeneron—in building new US production facilities across sterile injectables, APIs, biologics, and gene therapies. Announced reshoring commitments total over $480 billion across 22 manufacturing sites and roughly 44,000 jobs, yet upstream equipment suppliers have not seen order flow commensurate with these pledges, raising questions about execution.U.S. Food and Drug AdministrationFDA Actions to Support and Strengthen Domestic Drug ManufacturingThe FDA announced multiple initiatives on June 29, 2026 to strengthen U.S. pharmaceutical manufacturing, including the PreCheck Pilot Program, Operation TrialBlazer, ANDA Prioritization Pilot Program, and updated inspection compliance programs. The PreCheck Pilot Program, designed to help companies building new domestic manufacturing facilities engage with the FDA earlier in the development process, announced seven participating companies: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. These programs aim to modernize regulatory oversight, streamline processes, and incentivize domestic investment to improve supply chain resilience and reduce dependence on foreign drug production.Business Wire BlogKriya Selected for FDA PreCheck Pilot ProgramKriya Therapeutics, a biotechnology company developing durable medicines for chronic diseases, has been selected by the U.S. FDA to participate in the FDA PreCheck Pilot Program following a competitive evaluation of its capabilities and commercial manufacturing facility plans. The company's manufacturing facility in Research Triangle Park, North Carolina will produce its pipeline of AAV-based gene therapy products currently under evaluation in clinical trials. The program enables early FDA engagement with manufacturing facilities to enhance regulatory predictability and support expanded U.S.-based manufacturing capacity for critical medicines.FinancialContent Business PageKriya Selected for FDA PreCheck Pilot ProgramKriya Therapeutics announced it has been selected by the U.S. Food and Drug Administration to participate in the FDA PreCheck Pilot Program following a competitive evaluation of the company's capabilities and commercial manufacturing facility plans. As part of the program, Kriya's manufacturing facility in Research Triangle Park, North Carolina will produce its pipeline of AAV-based gene therapy products for chronic diseases currently in clinical trials. The initiative aims to enhance regulatory predictability for new facilities while supporting increased U.S.-based manufacturing capacity for critical medicines.YahooBIO 2026: Cell and gene therapy firms outline their use of AI in manufacturingCell and gene therapy companies discussed their use of artificial intelligence in manufacturing at the BIO International Convention (BIO 2026) held on June 22, 2026, in San Diego, California. Fraser Wright of Kriya Therapeutics highlighted how AI enabled the company to evaluate approximately 80 different constructs for manufacturability and analyze around 100 million data points from their integrated manufacturing platform to optimize yield and efficiency. Opus Genetics, another panel participant developing gene therapies for inherited retinal diseases, noted challenges from requiring very small batch sizes that limit their batch history data.VentureRadarNew Funding Rounds in "AAV gene therapy"Multiple biotechnology companies have announced recent funding rounds to develop gene therapies, including AAV-based treatments for vision, CNS, and heart diseases. Notable funding amounts include $320M for Kriya Therapeutics and over $125M for Ray Therapeutics.The Manila TimesKriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy PlatformKriya Therapeutics announced multiple presentations at the ASGCT 2026 meeting in Boston, highlighting advances in their gene therapy platform and ongoing programs for chronic diseases. The presentations include developments in delivery approaches, product quality assays, and scalable manufacturing processes.